Promotion of neuronal integration in neural stem cell grafts
AssigneeLife & Brain GmbH
InventorsOliver Brüstle, Philipp Koch, Julia Ladewig
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of diseases or disorders of the nervous system. In particular, the invention relates to the treatment of diseases or disorders of the nervous system by stem cell therapy, in particular therapy with neural precursor cells. In preferred aspects of the invention, inhibitors of chemoattraction are administered prior to, concomitantly with, or subsequently to the administration of neural precursor cells.
Claims13
A method of promoting migration of immature neurons from a site of transplantation in a patient suffering from a disease or disorder of the nervous system, said method comprising administering to the patient at a transplantation site a neural precursor cell and an inhibitor of chemoattraction selected from the group consisting of endostatin or a variant thereof having at least 90% amino acid sequence identity to human endostatin and having chemoattractant inhibitory activity, angiostatin or a variant thereof having at least 90% amino acid sequence identity to human angiostatin and having chemoattractant inhibitory activity, a VEGF inhibitor, a VEGFR inhibitor, a FGF2 inhibitor, and a FGF2R inhibitor, thereby promoting migration of the immature neurons from the site of transplantation.
A method of enhancing the effectiveness of therapy with transplanted neural precursor cells by promoting migration of immature neurons from the transplantation site, said method comprising administering to a patient undergoing said therapy neural precursor cells and an inhibitor of chemoattraction selected from the group consisting of endostatin or a variant thereof having at least 90% amino acid sequence identity to human endostatin and having chemoattractant inhibitory activity, angiostatin or a variant thereof having at least 90% amino acid sequence identity to human angiostatin and having chemoattractant inhibitory activity, a VEGF inhibitor, a VEGFR inhibitor, a FGF2 inhibitor, and a FGF2R inhibitor, thereby enhancing the effectiveness of the therapy with the transplanted neural precursor cells.
A method of promoting migration of immature neurons from a site of transplantation into surrounding tissue, said method comprising administering to a patient a neural precursor cell and an inhibitor of chemoattraction that promotes migration of the immature neurons into the surrounding tissue, said inhibitor selected from the group consisting of endostatin or a variant thereof having at least 90% amino acid sequence identity to human endostatin and having chemoattractant inhibitory activity, angiostatin or a variant thereof having at least 90% amino acid sequence identity to human angiostatin and having chemoattractant inhibitory activity, a VEGF inhibitor, a VEGFR inhibitor, a FGF2 inhibitor, and a FGF2R inhibitor.
A method of promoting migration of an immature neuron from a site of transplantation, the method comprising contacting transplanted neural precursor cells with an inhibitor of chemoattraction selected from the group consisting of endostatin or a variant thereof having at least 90% amino acid sequence identity to human endostatin and having chemoattractant inhibitory activity, angiostatin or a variant thereof having at least 90% amino acid sequence identity to human angiostatin and having chemoattractant inhibitory activity, a VEGF inhibitor, a VEGFR inhibitor, a FGF2 inhibitor, and a FGF2R inhibitor, wherein the inhibitor of chemoattraction promotes migration of the immature neuron from the transplantation site.
Dependencies are inferred from the claim text.